153 related articles for article (PubMed ID: 16889898)
1. Emerging applications for phospho-proteomics in cancer molecular therapeutics.
Moran MF; Tong J; Taylor P; Ewing RM
Biochim Biophys Acta; 2006 Dec; 1766(2):230-41. PubMed ID: 16889898
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomics and cancer research.
Ashman K; Villar EL
Clin Transl Oncol; 2009 Jun; 11(6):356-62. PubMed ID: 19531450
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
5. Global and site-specific quantitative phosphoproteomics: principles and applications.
Macek B; Mann M; Olsen JV
Annu Rev Pharmacol Toxicol; 2009; 49():199-221. PubMed ID: 18834307
[TBL] [Abstract][Full Text] [Related]
6. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.
Fang B; Haura EB; Smalley KS; Eschrich SA; Koomen JM
Biochem Pharmacol; 2010 Sep; 80(5):739-47. PubMed ID: 20361944
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomics for oncology discovery and treatment.
Stern DF
Expert Opin Ther Targets; 2005 Aug; 9(4):851-60. PubMed ID: 16083347
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomics by mass spectrometry and classical protein chemistry approaches.
Salih E
Mass Spectrom Rev; 2005; 24(6):828-46. PubMed ID: 15538747
[TBL] [Abstract][Full Text] [Related]
9. Identification and quantitation of signal molecule-dependent protein phosphorylation.
Groen A; Thomas L; Lilley K; Marondedze C
Methods Mol Biol; 2013; 1016():121-37. PubMed ID: 23681576
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomics-based network medicine.
Liu Z; Wang Y; Xue Y
FEBS J; 2013 Nov; 280(22):5696-704. PubMed ID: 23751130
[TBL] [Abstract][Full Text] [Related]
11. Combining Metabolic ¹⁵N Labeling with Improved Tandem MOAC for Enhanced Probing of the Phosphoproteome.
Thomas M; Huck N; Hoehenwarter W; Conrath U; Beckers GJ
Methods Mol Biol; 2015; 1306():81-96. PubMed ID: 25930695
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous quantification of protein phosphorylation sites using liquid chromatography-tandem mass spectrometry-based targeted proteomics: a linear algebra approach for isobaric phosphopeptides.
Xu F; Yang T; Sheng Y; Zhong T; Yang M; Chen Y
J Proteome Res; 2014 Dec; 13(12):5452-60. PubMed ID: 25403019
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
Matta A; Ralhan R; DeSouza LV; Siu KW
Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
[TBL] [Abstract][Full Text] [Related]
14. Catch me if you can: mass spectrometry-based phosphoproteomics and quantification strategies.
Eyrich B; Sickmann A; Zahedi RP
Proteomics; 2011 Feb; 11(4):554-70. PubMed ID: 21226000
[TBL] [Abstract][Full Text] [Related]
15. Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry.
Jin LL; Tong J; Prakash A; Peterman SM; St-Germain JR; Taylor P; Trudel S; Moran MF
J Proteome Res; 2010 May; 9(5):2752-61. PubMed ID: 20205385
[TBL] [Abstract][Full Text] [Related]
16. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Weber C; Schreiber TB; Daub H
J Proteomics; 2012 Feb; 75(4):1343-56. PubMed ID: 22115753
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
Murray HC; Dun MD; Verrills NM
Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
[TBL] [Abstract][Full Text] [Related]
19. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
20. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
